DexCom price target raised to $160 from $150 at Piper Sandler

Piper Sandler analyst Matt O’Brien raised the firm’s price target on DexCom to $160 from $150 and keeps an Overweight rating on the shares. The company reported Q2 results that beat estimates and increased guidance by more than the beat, which still looks “readily achievable,” the analyst tells investors in a research note. Piper says the outlook for the business remains “excellent” and that the stock is still its favorite large cap name.